Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 84 publications.

Talbird SE, Carrico J, La EM, Carias C, Marshall GS, Roberts CS, Chen YT, Nyaku MK. Impact of routine childhood immunization in reducing vaccine-preventable diseases in the US. Pediatrics. 2022 Jul 13. doi: 10.1542/peds.2021-056013

Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Mellott CE, Marshall GS, Roberts C. Value of the immunization program for children in the 2017 US birth cohort. Pediatrics. 2022 Jul 13. doi: 10.1542/peds.2021-056007

Anderson S, Talbird SE, Nossov M, Beattie N, Diaz-Mitoma F. Cost-effectiveness of 3-antigen vs. single-antigen vaccine for prevention of hepatitis B in adults in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002

Carrico J, Mellott C, Talbird S, Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Anderson S, Mauskopf J, Talbird SE, White A, Meenakshi S. Antiseizure medications and oral contraceptives: impact of enzyme inducers on pregnancy outcomes and costs. Epilepsy Behav. 2021 Dec;125:108368. doi: 10.1016/j.yebeh.2021.108368

Anderson S, Talbird SE, Fishman J, Mody-Patel N, Sarda SP. Budget impact of pegcetacoplan, a complement c3 inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria in US adults. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.

Talbird S, Carrico J. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Presented at the 2021 National Adult and Influenza Immunization Summit Virutal Meeting; August 26, 2021.

Carrico J, Talbird SE, La EM, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine. 2021 Aug 23;39(36):5187-97. doi: 10.1016/j.vaccine.2021.07.029

Davis A, Jiang J, Talbird S, Turpin RS, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual Digestive Disease Week (DDW) Conference; May 21, 2021. Previously presented at the 2021 AMCP Conference.

Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6

Davis AE, Jiang J, Talbird SE, Turpin R, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual AMCP; April 2021.

Anderson S, Talbird S, Fishman J. Cost per responder analysis for pegcetacoplan and eculizumab in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Blood. 2021;138(Suppl 1):4956. doi: 10.1182/blood-2021-153190

Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039

La EM, Carrico J, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Current estimates of the impact of routine childhood immunizations in reducing vaccine-preventable diseases in the United States. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.

Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea CS. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2020 Aug 6;1-12. doi: 10.1080/21645515.2020.1780847

La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371

Graham J, Wolfson LJ, Kyle J, Perez Bolde-Villarreal C, Guarneros-DeRegil DB, Monsanto H, Pillsbury M, Talbird S, Daniels VJ. Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective. Hum Vaccin Immunother. 2019 Dec 18;16(4):886-94. doi: 10.1080/21645515.2019.1672491

Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y

Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788

Savatt JA, Azzariti DR, Faucett A, Florin J, Ledbetter DH, Rangel Miller V, Palen E, Rehm HL, Rhode J, Rogers L, Talbird S, Trutoiu L, Vidal JA, Waggoner C, Rooney Riggs E, Lese Martin C. Expanding patient data sharing: GenomeConnect's pilot to engage external registries in data sharing. Poster presented at the 2019 National Society of Genetic Counselors (NSGC) 38th Annual Conference; November 2019. Salt Lake City, UT.

Talbird SE, Savatt JM. Patient data sharing of genetic and health information informs genetics discovery and fuels research. Presented at the 2019 Rare Disease Innovation and Partnering Summit; June 14, 2019. Boston, MA.

Talbird SE, La EM. Treatment patterns, health care resource use, and financial impact of CADASIL in the United States. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults in the United States. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Savatt JM, Azzariti DR, Faucett WA, Ledbetter DH, Rangel Miller V, Palen E, Rehm HL, Rhode J, Rogers L, Talbird S, Trutoiu L, Vidal JA, Rooney Riggs E, Lese Martin C. ClinGen's patient data sharing program: leveraging data sharing experience from GenomeConnect to broaden patient data sharing efforts. Poster presented at the 2019 Curating the Clinical Genome Conference; May 2019. Washington, DC.

La EM, Talbird SE, Kanadanian KV, Huang L, Fain J, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019 Apr 3;15(4):978-86. doi: 10.1080/21645515.2018.1556074

Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801

Talbird SE, La EM, Maurer N, Vidal J, Rangel Miller V. Is the CADASIL Family Registry research ready? Poster presented at the 2018 National Organization for Rare Disorder (NORD) Rare Diseases & Orphan; October 15, 2018. Washington, DC.

La EM, Talbird SE, Kanadanian KV, Fain J, Huang L, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Poster presented at the 2018 IDWeek Conference; October 4, 2018. San Francisco, CA.

Talbird SE, La EM, Carrico J, Poston S, Poirrier J, DeMartino JK, Hogea C. Projected burden of vaccine-preventable diseases in older adults in the United States: impact of population aging. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Supplement 3):S225.

La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862. doi: 10.1111/ecc.12862

Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.

Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.

Talbird SE, Hogea CS, Meyers J, Carrico J, Buck PO. Cost-effectiveness of a 10-year revaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (TDaP) vaccine among individuals with pre-existing asthma in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S153. doi: 10.1016/j.jval.2018.04.1062

Graham J, Talbird SE, Monsanto H, Perez Bolde-Villareal C, Daniels V, Pillsbury M, Wolfson LJ. Budget impact of a one-dose varicella vaccination program using outputs of a dynamic transmission model: Mexican national perspective. Poster presented at the 17th Annual Congress of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE); November 2017. Cancun, Mexico.

Talbird SE, La EM, Mauskopf J, Krueger WS, Altland A, Daniels VJ, Pillsbury M, Wolfson LJ. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A325.

Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.

Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541

Cairns B, Kowolenko M, Talbird S, Britt T, Shanley L. Applying artificial intelligence to the diagnosis of rare diseases. Presented at the UNC Renaissance Computing Institute (RENCI); February 15, 2017. Chapel Hill, NC.

Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349

Nash Smyth E, La E, Talbird S, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use (HCRU) associated with repeatedly treated metastatic squamous cell carcinoma of the head and neck (SCCHN) in the United Kingdom (UK). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 9, 2015. Milan, Italy.

Talbird SE, Brogan AJ, La EH, Perard R. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in France and Spain. Poster presented at the Health Technology Assessment international; June 14, 2015. Oslo, Norway.

Talbird SE, Mauskopf JA, Yang K. Review of cost-effectiveness analyses of varicella vaccination: which model structure assumptions and input parameters matter? Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the United Kingdom. Poster presented at the 20th International AIDS Conference; July 20, 2014.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.

Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295

Brennan VK, Talbird SE, Beard SM, Brogan AJ, Flanagan D, Delpech V, Bosanquet N, Fisher M. The public health and economic impact from earlier diagnosis and earlier antiretroviral treatment of HIV in the UK. Poster presented at the 14th European AIDS Conference/EACS; October 16, 2013.